SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ZyVersa Therapeutics, Inc. (ZVSA) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 27/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ZVSA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-4.18
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-272.45 |
$0.00 |
$-13.2M |
- |
| 2021 |
$-173.66 |
$0.00 |
$-8.91M |
- |
| 2022 |
$-930.25 |
$0.00 |
$-759.1M |
- |
| 2023 |
$-1,089.67 |
$0.00 |
$-98.3M |
- |
| 2024 |
$-8.48 |
$0.00 |
$-9.41B |
- |
| 2025 |
$-4.18 |
$0.00 |
$-24.95B |
- |
